Kymera Therapeutics will announce Q3 2025 financial results on November 4, with an accompanying video conference call.
Quiver AI Summary
Kymera Therapeutics, a clinical-stage biopharmaceutical company focused on developing oral small molecule degrader medicines for immunological diseases, will announce its financial results for the third quarter of 2025 on November 4, 2025. The company will host a video conference call and webcast at 8:30 a.m. ET on that day, with access available through their website. Kymera is pioneering targeted protein degradation to create innovative therapies, having already moved its first degrader into clinical trials. Established in 2016, the company has gained recognition as one of Boston's top workplaces. More information about their projects can be found on their website or social media platforms.
Potential Positives
- Kymera Therapeutics is advancing a new class of oral small molecule degrader medicines, positioning itself as a pioneer in targeted protein degradation (TPD) for immunological diseases.
- The company will report its third quarter financial results soon, indicating engagement with investors and transparency in financial reporting.
- Kymera has advanced the first degrader into clinical trials for immunological diseases, suggesting progress and potential efficacy in its drug development pipeline.
- Recognition as one of Boston’s top workplaces highlights a positive company culture and may attract talent and investors.
Potential Negatives
- None
FAQ
When will Kymera Therapeutics report its third quarter financial results?
Kymera Therapeutics will report its third quarter financial results on November 4, 2025.
How can I join the Kymera Therapeutics video conference?
You can join the video conference by registering via the provided link or visiting the "News and Events" section on Kymera's website.
What is Kymera Therapeutics focused on developing?
Kymera Therapeutics is focused on developing a new class of oral small molecule degrader medicines for immunological diseases.
Where can I find more information about Kymera Therapeutics?
More information about Kymera Therapeutics can be found on their official website at www.kymeratx.com.
What is targeted protein degradation (TPD)?
Targeted protein degradation (TPD) is a novel approach to develop medicines targeting disease pathways that conventional therapeutics cannot access.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$KYMR Insider Trading Activity
$KYMR insiders have traded $KYMR stock on the open market 20 times in the past 6 months. Of those trades, 5 have been purchases and 15 have been sales.
Here’s a breakdown of recent trading of $KYMR stock by insiders over the last 6 months:
- BROS. ADVISORS LP BAKER has made 2 purchases buying 655,500 shares for an estimated $28,842,000 and 0 sales.
- PARTNERS L P/IL BVF has made 3 purchases buying 317,167 shares for an estimated $13,955,348 and 0 sales.
- BRUCE N. JACOBS (Chief Financial Officer) sold 79,220 shares for an estimated $3,961,380
- JARED GOLLOB (Chief Medical Officer) has made 0 purchases and 5 sales selling 62,690 shares for an estimated $3,846,093.
- NELLO MAINOLFI (Chief Executive Officer) has made 0 purchases and 2 sales selling 60,000 shares for an estimated $2,940,000.
- ELENA RIDLOFF has made 0 purchases and 3 sales selling 16,500 shares for an estimated $778,200.
- JEFFREY W. ALBERS has made 0 purchases and 2 sales selling 11,349 shares for an estimated $607,050.
- PAMELA ESPOSITO sold 5,000 shares for an estimated $245,185
- JEREMY G CHADWICK (Chief Operating Officer) sold 2,575 shares for an estimated $75,435
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$KYMR Hedge Fund Activity
We have seen 128 institutional investors add shares of $KYMR stock to their portfolio, and 80 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC added 1,022,760 shares (+23.2%) to their portfolio in Q2 2025, for an estimated $44,633,246
- CAPITAL RESEARCH GLOBAL INVESTORS added 896,992 shares (+245.6%) to their portfolio in Q2 2025, for an estimated $39,144,730
- JANUS HENDERSON GROUP PLC removed 751,274 shares (-97.5%) from their portfolio in Q2 2025, for an estimated $32,785,597
- BAKER BROS. ADVISORS LP added 655,500 shares (+10.9%) to their portfolio in Q2 2025, for an estimated $28,606,020
- DEERFIELD MANAGEMENT COMPANY, L.P. added 653,000 shares (+inf%) to their portfolio in Q2 2025, for an estimated $28,496,920
- WELLINGTON MANAGEMENT GROUP LLP removed 624,812 shares (-10.4%) from their portfolio in Q2 2025, for an estimated $27,266,795
- CITADEL ADVISORS LLC added 516,382 shares (+20614.1%) to their portfolio in Q2 2025, for an estimated $22,534,910
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$KYMR Analyst Ratings
Wall Street analysts have issued reports on $KYMR in the last several months. We have seen 13 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a "Buy" rating on 10/22/2025
- Mizuho issued a "Outperform" rating on 10/21/2025
- Oppenheimer issued a "Outperform" rating on 10/01/2025
- Truist Securities issued a "Buy" rating on 09/30/2025
- HC Wainwright & Co. issued a "Buy" rating on 09/18/2025
- RBC Capital issued a "Outperform" rating on 09/16/2025
- Wells Fargo issued a "Overweight" rating on 06/26/2025
To track analyst ratings and price targets for $KYMR, check out Quiver Quantitative's $KYMR forecast page.
$KYMR Price Targets
Multiple analysts have issued price targets for $KYMR recently. We have seen 17 analysts offer price targets for $KYMR in the last 6 months, with a median target of $64.0.
Here are some recent targets:
- Jeet Mukherjee from BTIG set a target price of $75.0 on 10/22/2025
- Joseph Catanzaro from Mizuho set a target price of $81.0 on 10/21/2025
- Geoff Meacham from Citigroup set a target price of $80.0 on 10/17/2025
- Jeff Jones from Oppenheimer set a target price of $63.0 on 10/01/2025
- Srikripa Devarakonda from Truist Securities set a target price of $68.0 on 09/30/2025
- Andrew S. Fein from HC Wainwright & Co. set a target price of $70.0 on 09/18/2025
- Etzer Darout from Barclays set a target price of $60.0 on 09/17/2025
Full Release
WATERTOWN, Mass., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing a new class of oral small molecule degrader medicines for immunological diseases, will report third quarter 2025 financial results on November 4, 2025. The Company will host a video conference call and webcast at 8:30 a.m. ET that day.
To join the video call or view the livestreamed webcast, please register via this link , or visit “ News and Events ” in the Investors section of the Company’s website at www.kymeratx.com . A replay of the webcast will be archived and available following the event.
About Kymera Therapeutics
Kymera is a clinical-stage biotechnology company pioneering the field of targeted protein degradation (TPD) to develop medicines that address critical health problems and have the potential to dramatically improve patients’ lives. Kymera is deploying TPD to address disease targets and pathways inaccessible with conventional therapeutics. Having advanced the first degrader into the clinic for immunological diseases, Kymera is focused on building an industry-leading pipeline of oral small molecule degraders to provide a new generation of convenient, highly effective therapies for patients with these conditions. Founded in 2016, Kymera has been recognized as one of Boston’s top workplaces for the past several years. For more information about our science, pipeline and people, please visit
www.kymeratx.com
or follow us on
X
or
LinkedIn
.
|
Investor and Media Contact:
Justine Koenigsberg Vice President, Investor Relations [email protected] [email protected] 857-285-5300 |
